Related Experiment Video

Updated: Apr 26, 2026

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

10.2K

Dinaciclib for the treatment of breast cancer

Carmen Criscitiello1, Giulia Viale, Angela Esposito

  • 1Istituto Europeo di Oncologia, Division of Early Drug Development for Innovative Therapies , Via Ripamonti 435, 20133 Milano , Italy +39 02 57489439 ; +39 02 94379224 ; giuseppe.curigliano@ieo.it.

Expert Opinion on Investigational Drugs
|August 10, 2014
PubMed
Abstract

Insights

Dinaciclib, a cyclin-dependent kinase (CDK) inhibitor, shows promise for treating breast cancer by targeting cell cycle progression. Further research is needed to identify biomarkers and explore combination therapies for enhanced efficacy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cyclin-dependent kinases (CDKs) are crucial regulators of gene transcription and cell cycle progression, making them significant targets in cancer therapy.
  • Dinaciclib (MK-7965) is an emerging inhibitor of CDK 1/2/5/9 with demonstrated preclinical efficacy and a favorable safety profile in early clinical trials.
  • The drug is currently being investigated for its potential in treating various hematological and solid tumors, including breast cancer.

Purpose of the Study:

  • To review the established role of CDKs in cancer biology and the therapeutic potential of CDK inhibition in breast cancer.
  • To summarize and analyze preclinical and clinical data pertaining to dinaciclib's application in breast cancer treatment.

Main Methods:

  • Literature review of CDK function in cancer.
  • Analysis of preclinical data for dinaciclib.
  • Review of clinical trial data for dinaciclib in breast cancer.

Main Results:

  • CDK inhibition represents a viable therapeutic strategy for breast cancer.
  • Dinaciclib has shown promising results in preclinical models and Phase I trials.
  • Further clinical evaluation of dinaciclib in breast cancer is warranted.

Conclusions:

  • Enhanced understanding of cancer cell cycle dysregulation is essential for developing novel CDK inhibitors.
  • Identifying biomarkers for dinaciclib responsiveness is crucial for patient stratification in clinical trials.
  • Investigating combination therapies involving dinaciclib with chemotherapy, endocrine, or targeted agents may improve treatment outcomes in breast cancer.
Keywords:
breast cancercyclin-dependent kinasescyclin-dependent kinases inhibitorsdinaciclib

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.3K
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

3.4K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

4.3K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
688
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.3K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K